# EVEREST-2 (NCT06051695)

> A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

No report yet. It can be ordered.

- Drugs tested: A2B694; A2B543

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06051695
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: A2 Biotherapeutics Inc.
- Conditions: Solid Tumor, Adult; Colorectal Cancer; NSCLC; Non Small Cell Lung Cancer; NSCLC, Recurrent; Non-Small Cell Squamous Lung Cancer; Pancreas Cancer; Pancreatic Neoplasm; Colorectal Adenocarcinoma; CRC; Colon Cancer; Rectal Cancer; Cancer; Ovarian Cancer; Ovarian Neoplasms; Mesothelioma; Mesothelioma, Malignant; Ovary Cancer; Lung Cancer; MESOM
- Interventions: A2B694; A2B543; xT CDx with HLA-LOH Assay
- Enrollment: 474
- Primary outcome: Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level
- Primary outcome: Phase 1: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Phase 2: The Overall Response Rate (ORR) for patients

## Indexed commentary on EVEREST-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X
- 3 YouTube videos
- 1 video on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=everest-2-nct06051695

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06051695", "email": "<work email>"}; the inbox owner confirms by the emailed link.